Dojindo日米共催ウェビナー: フェロトーシス研究の最前線

 

   日時： 2025年11月13日, 11月20日（木）
 
オンライン開催：参加無料　発表言語：英語
 
 

 

日米共催DOJINDOウェビナー(全2回)を開催いたします。

NatureやScience誌に多数の論文を発表している、フェロトーシス研究の最前線を牽引するUC BerkeleyとStanfordの教授が、
「フェロトーシス研究の最前線〜世界のトップ研究者が解き明かす”細胞死の新しい扉”〜」をテーマに、疾患治療への応用の可能性を直接解説します！
 

＜本ウェビナーで学べるポイント＞

・フェロトーシスの最新メカニズム

・抵抗性がん治療への応用戦略

・創薬・診断に向けた新しい研究アプローチ

  • 申込みは終了しました。

上記よりすべてのプログラムへご参加いただけます。

第１回   11月13日 9:00-10:00 (日本時間)

Mechanisms and therapeutic targeting of ferroptosis

James Olzmann

Doris Howes Calloway
Chair and Professor
UC Berkeley

Dr. James Olzmann is the Doris H. Calloway Chair and Professor at the University of California, Berkeley. He holds joint appointments in the Departments of Molecular & Cell Biology and Nutritional Sciences & Toxicology. In this seminar, Dr. Olzmann will highlight recent discoveries from his lab on the mechanisms that govern oxidative lipid damage and ferroptosis, a regulated form of cell death. Using genetic screening approaches, his team has identified critical regulators of cellular responses to lipid peroxidation, such as FSP1, an oxidoreductase that functions parallel to GPX4 to recycle membrane antioxidants and suppress ferroptosis. Recent findings also reveal that FSP1 protects neutral lipids in lipid droplets, and that its inhibition sensitizes cancer cells to ferroptosis. These insights uncover key aspects of lipid biology and oxidative stress resilience, while pointing to new therapeutic opportunities. Targeting ferroptosis resistance mechanisms offers a promising strategy to overcome drug resistance in cancer and related diseases.

第２回   11月20日 9:00-10:00 (日本時間)

Exploring novel cell death phenotypes in cancer

Scott Dixon

Professor of Biology
Stanford Univ

Non-apoptotic cell death mechanisms that can be induced by small molecules are of fundamental mechanistic interest and may be useful to treat certain cancers. We have previously identified small molecules (erastin, RSL3) that induce an iron-dependent, non-apoptotic form of cell death termed ferroptosis. Through chemical genetic screening we have identified roles for several lipid metabolic enzymes in this non-apoptotic cell death mechanism. More recently, we have identified a clinical candidate oncology drug that activates a novel, lipid-dependent mechanism of non-apoptotic cell death that is distinct from ferroptosis. This lethal mechanism requires the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR). TECR is canonically involved in the synthesis of very long chain fatty acids but seems to promote non-apoptotic cancer cell death in response to tegavivint by synthesizing a saturated long-chain fatty acid, palmitate. I will discuss these findings in the context of our overall search for novel ways to induce cancer cell death for the treatment of cancers.

製品分類一覧

分類一覧から探す

お探しの検索ワードを入力してください